Ocumension Therapeutics
歐康維視生物

2024

Environmental Social and Governance Report

Ocumension Therapeutics
(Incorporated in the Cayman Islands with limited liability)
Stock code: 1477

Table of Content

About the Report

The Report is the fifth Environmental, Social and Governance (ESG) report issued by Ocumension Therapeutics, aiming to introduce the Group's ESG strategies, practices, measures and results from both environmental and social perspectives to our stakeholders.

Reporting scope

The Report covers Ocumension's principal operations in China, wherein the key performance indicators (KPIs) in environmental area mainly cover the Group's office buildings and laboratories in Shanghai, Suzhou, Beijing and Hangzhou as well as Suzhou manufacturing plant, and the KPIs in social area mainly cover the Company and all its subsidiaries in China. The reporting period is from 1 January 2024 to 31 December 2024 (Reporting Period).

Reporting definition

For ease of presentation, Ocumension Therapeutics is also referred to as "Ocumension", "the Group" or "we/us".

Access method

The electronic version of the Report is accessible from the official website of the Group at https://www.ocumension.com/ and the website of HKEx at www.hkexnews.hk.

Reporting principles

The Report is prepared in accordance with the Environmental, Social and Governance Reporting Guide (the ESG Reporting Guide) set out in Appendix C2 to the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited.

The Report follows the principles set forth in the ESG Reporting Guide, including:

Materiality: The Group identifies key ESG issues through stakeholder engagement and materiality assessment, and disclosures accordingly in the ESG Report.

Quantitative: The Report uses quantitative data to present KPIs in environmental and social areas, with narratives provided to explain the purpose and impacts.

Balance: Based on this principle, the contents of the Report reflect objective facts related to the Group's ESG management.

Consistency: The Report adopts the same data disclosure and statistical methods as the 2023 Report did to ensure the comparability of information.

The Report is provided in Traditional Chinese and English for readers' reference. In case of any discrepancy between the two versions, the traditional Chinese version shall apply and prevail.

About Ocumension

Ocumension is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing, and commercialising first- or best-in-class ophthalmic therapies. On 10 July 2020, Ocumension was listed on the Main Board of the HKEx with a stock code: 1477.

Our mission To provide Chinese ophthalmic patients with excellent and comprehensive treatment solutions through continuous scientific search and innovation

Our vision To provide a world-class pharmaceutical total solution to address significant unmet ophthalmic medical needs in China

Since our inception, we have been focusing on building a platform integrating specialised capabilities in each major functionality involved in an ophthalmic drug's development cycle, from research and development (R&D), manufacturing, to commercialisation. Meeting the treatment needs of patients is the key responsibility of Ocumension, and it is also the concept we have long-term adhered to. Our products serve as carriers of this business philosophy, while doctors are our partners to practice.

As of the end of 2024, the Group had 34 drug assets for both front and back of the eye that constitute a complete product line of ophthalmic drugs, of which 21 products were in the commercialization stage, 3 products had entered phase III clinical trials, and 2 products had entered the commercial registration stage.

In 2024, products of Ocumension that were certified, approved, and made progress in clinical research and development were detailed below:

In September 2024, OT-1001 (brand name: Zerviate®), a potent and highly selective histamine H-1 receptor antagonist, was officially approved for marketing registration by the National Medical Products Administration (NMPA). The drug is mainly used to treat ocular itching associated with allergic conjunctivitis. It has previously been marketed in the United States and received positive feedback.

In July 2024, the Biologics License Application (BLA) for Abciximab Intraocular Injection Solution (OT-702) was accepted by the Center for Drug Evaluation (CDE) of NMPA. The product is used for the treatment of pathological neovascularization-related retinal and choroidal eye diseases.

In April 2024, the Phase III clinical trial of dexamethasone implant (OT-502) achieved its primary endpoint, with study results demonstrating the product's safety and efficacy in controlling inflammation after cataract surgery. In September, the new drug application for OT-502 was accepted by the CDE.

Product pipelines



Key ESG Performance of 2024

Total energy consumption
15,623.82 MWh

Energy consumption intensity
37.44 MWh per million RMB revenue

Year-on-year decrease 27.0%

Total water consumption
70,782.80 tonnes

Total water consumption intensity
169.62 tonnes per million RMB revenue

Year-on-year decrease 23.5%

Total hazardous waste emission
36.21 tonnes

Hazardous waste emission intensity
86.77 kg per million RMB revenue

Year-on-year decrease 1.8%

Total workforce 489

up 10.1% year on year

47.4% of the workforce was female

Product pipelines 100%

Average training hours 35.7 hours

Suppliers 1,104

an increase of 12.5% year on year

Registered trademarks 243

Patents 43

Customer complaints 0

Awards and Honours

Ocumension was awarded the title of
2024 (11th) Greater Suzhou Best Employer
by Suzhou Industrial Park Human Resources Development Co., Ltd.

Ocumension was awarded the title of
Top Ten Employers in Wuzhong District
by the People's Government of Wuzhong District.

Ocumension was awarded the
2024 Social Responsibility Award
by JD Health International Inc.

ESG Governance

The Board announcement

The Group highly values ESG-related matters that the Board of directors of the Company (the Board) takes overall responsibility for ESG-related matters, the integration of ESG-related matters into the Group's development strategy and guiding the management and.

The Board discusses the latest development in ESG-related matters every year. During the Reporting Period, the Board held several meetings to discuss and review ESG-related matters such as the Group's manpower budget, compensation and welfare, product project approval, intellectual property rights, and so on.

Looking to the future, the Group will continue to promote green low-carbon transformation, strengthen social responsibility, improve corporate governance standards, in order to maximize the comprehensive value of the economy, society and the environment. We believe that through continuous efforts and innovation, the Group will contribute more to sustainable development.

ESG management strategy

At the Group, we are seeking continuous improvement of the sustainable development system and optimise our internal management while providing advanced high-quality ophthalmic pharmaceutical products and services to Chinese consumers. We have established a three-level ESG governance structure composed of the Board, management, and an ESG Working Group composed of major departments of the Group, thus creating a top-down ESG management system.

The Board assumes full responsibility for the Group's ESG matters, and is responsible for formulating ESG management policies, reviewing ESG-related matters on a regular basis, identifying and assessing related risks, and ensuring that the Group has established appropriate and effective ESG risk management and internal control systems. Meanwhile, the Board regularly reviews the performance of the Group on the relevant objectives of ESG and approves the information disclosed in the ESG Report. The Audit Committee of the Group, as the representative of the Board, assists the Board in the overall management and supervision of the ESG management work of the Group and ESG information disclosure.

The management of the Group is responsible for implementing ESG risk management and internal control systems, and the Board of Directors Office takes the lead in reporting the progress and result of the ESG-related work to the Board. The ESG Working Group is responsible for the daily management and reporting of ESG-related matters.



Communication with stakeholders

The requirements and expectations of stakeholders are an important basis for Ocumension to determine the direction of sustainable development. The government and regulators, shareholders and investors, employees, customers/patients, partners/suppliers, peer companies/industry associations, media and communities are the Group's main stakeholders. We have maintained effective communication with various stakeholders to keep abreast of their demands and expectations, and to discuss and respond to the ESG issues they concern, to determine the focus and direction of our ESG management.

Stakeholders	Expectations and concerns	Communication channels	Communication frequency
Government and regulators	Business ethics and integrity Payment of taxes Industry cooperation and development	Compliance management Voluntary taxation Complying with national policies Continuous R&D and innovation Risk analysis and reporting Timely reporting of adverse events Active participation in government projects	Multiple times per year
Shareholders and investors	Business ethics and integrity Return on investment Standardised management and governance Information disclosure	Announcements and circulars Financial reporting Shareholders' meeting Roadshow Investor meetings	Multiple times per year
Employees	Employee rights and benefits Employee training and development Occupational health and safety	Regular meetings and training Employee care activities Internal websites	Multiple times per year
Customers/ patients	Product quality and safety Product innovation and development Protection of rights and interests of customers and patients Responsible marketing and customer satisfaction	Daily communication and meetings Training courses Academic seminar R&D cooperation Service hotline and email	Multiple times per month
Partners/ suppliers	Technical exchange and communication Loyal implementation of agreements performance Industry cooperation and development Sustainable supply chain management	Daily communication and meetings Business visits to factories Audit and performance assessment	Multiple times per month
Peer companies/ industry associations	Product quality and safety Industry cooperation and development Listening to patient feedback	Industry exchange Benchmarking	Multiple times per month
Media	Product quality and safety Community welfare	Official website Daily communication	Multiple times per month
Community	Community welfare	Community welfare Public welfare activities	Multiple times per month

Materiality assessment

The Group conducts regular materiality assessments to identify key areas of focus for ESG management in the future. The specific steps are as follows:

Identifiy ESG issues

We have identified ESG issues relevent to the Group in accordance with the requirements of the ESG Reporting Guide, and in line with peer benchmarking and expert research and judgement.

Determine the materiality

We assessed the materiality of every issue from the two perspectives of "Importance to Ocumension's business development" and "Impact on stakeholders" through interviews and materiality evaluation questionnaires with internal stakeholders of the Group, then created a materility assessment matrix.

Verify the assessment results

Management and the ESG Working Group reviewed and comfirmed the assessment results.

In 2024, as there were no significant changes in the Group's business, taking into account the ESG trend and the Company's actual situation, the Group used the results of materiality assessment in 2023 after discussion and analysis. The specific ESG materiality matrix is as follows:

Environmental topics

Social topics

Governance topics

Ocumension's Materiality Matrix



Results of materiality assessment



Responsible Operation to Consolidate Development Foundation

Contribution to the SDGs

Sound corporate governance is the foundation for compliance operation and efficient management. In strict accordance with the laws and regulations of the regions where businesses are conducted, Ocumension establishes a sound governance mechanism for compliance operation, practices high standards of business ethics, and strengthens information security and privacy protection. These efforts provide a solid guarantee for the Company's sustainable development.

Internal control and risk management

Ocumension strictly abides by the Criminal Law of the People's Republic of China《中華人民共和國刑法》, the Pharmaceutical Administration Law of the People's Republic of China《中華人民共和國藥品管理法》, the Anti-Unfair Competition Law of the People's Republic of China《中華人民共和國反不正當競爭法》and other laws and regulations, and it has established a sound risk identification and compliance management system, ensuring compliance operation.

We have established a compliance committee led by the CEO to guide, supervise, and coordinate the compliance management of the Group. We have formulated the Internal Audit Requirements《內部審計規定》to clarify the responsibility and authority of the Internal Audit Department, and the independence requirements for the department, as well as the internal audit methods and standards, including developing an audit plan, clarifying the audit scope, reporting deficiencies, recording and tracking the rectification processes, regularly reporting internal control audits to management, and implementing appropriate off-duty audit procedures on resignation or transfer of senior management.

In terms of risk management, we effectively identify, actively manage, and prevent compliance risks through the establishment of Risk Management Manual《風險管理手冊》, Contract Management Regulations《合同管理規定》and Guidelines for the Promotion of Pharmaceutical Products《藥品推廣準則》and other policies. By implementing the 6-step risk management procedures, i.e., risk identification, risk assessment, risk response, risk testing, risk monitoring and risk reporting, we formulate targeted risk response measures based on the prioritisation of risks, and conduct a reassessment of the residual risks.

Risk identification	Risk assessment	Risk response	Risk testing	Risk monitoring	Risk reporting
Identify internal and external risks in a systematic and regular manner	Assess the likelihood and impact of the risk	Determine risk response strategies and implement response plans	Regularly test risk management and response capabilities	Generally evaluate the effectiveness of the design and implementation of risk response strategies	Report risks and risk management in a regular and systematic manner

In 2024, the Internal Audit Department conducted an annual risk assessment and audit work. With respect to the internal control deficiencies identified during the audit process, we made audit recommendations, implemented the rectification plan and tracked it for checks to ensure 100% completion of rectification and reported the results to the Audit Committee and the Management layer regularly.

Business ethics

Adhering to business ethics, Ocumension has formulated the Compliance Manual《合規手冊》to standardize compliance and business ethics practices, and strictly prohibits bribery, extortion, fraud and money laundering. All new joiners are required to complete the training on Compliance Manual《合規手冊》within one month upon getting on board, and sign a Letter of Commitment on Compliance Manual《合規手冊承諾書》. In 2024, we developed the Employee Expense Reimbursement Review System《員工費用報銷複核制度》to review the compliance, truthfulness, reasonableness and accuracy of employee expense reimbursement. Meanwhile, we completed the registration of all medical representatives in 2024 and updated the Drug Promotion Guidelines《藥物推廣準則》to standardize the registration of medical representatives and strengthen the supervision of anti-corruption in the medical field.

We ensure the standard implementation of all kinds of operation activities through daily compliance supervision, reporting, cultural promotion, and implementation and carried out compliance evaluation for each employee. Meanwhile, we have incorporated compliance evaluation into the performance assessment of employees and their superior leaders, thereby enhancing the compliance awareness of employees at all levels.

The Group has set up a compliance office for all employees to receive compliance consultation and compliance reports submitted by all employees. We keep confidential information related to compliance consultation and compliance reports as well as employee information. No employee will be punished by the Group or retaliated by others as a result of a compliance report. For those who retaliated, the Group will punish them in accordance with the relevant rules and regulations. We have established whistle-blowing channels for both internal and external stakeholders and introduced relevant terms in the agreement template of the Company.

Reporting channels mainly include:

- Internal reporting email：**compliance@ocumension.com**
- Internal reporting hotline：**+86-21-2289-3633**
- External stakeholder reporting email：**complaintbox@ocumension.com**

The Group attaches great importance to the dissemination of compliance awareness and concepts among all employees. We formulate compliance training plans every year and regularly organize diversified training sessions by means of email, online learning platforms and external training. The training sessions cover a range of topics, including anti-fraud, interpretation of the Guidelines for the Promotion of Pharmaceutical Products《藥品推廣準則》, dissemination of the Compliance Manual《合規手冊》and compliance system, and guidelines for clinical and academic promotional meetings. In 2024, the coverage of our compliance training was 100%. We also conducted anti-corruption training for the Board based on the Compliance Manual《合規手冊》, the Staff Anti Fraud Training《全員反舞弊培訓》, the Guidelines for Directors' Integrity Affairs《董事誠信實務指南》, and the Guidelines for Affairs of the Listed Company Anti-Corruption System《上市公司防貪系統實務指南》, to jointly promote a clean and honest industry atmosphere.

Our commitment to business ethics management extends to our partners as well. For business partners such as suppliers, manufacturers, contractors and consultants, we have formulated the Partner Code of Conduct《合作夥伴行為準則》. The policy regulates business ethics practices such as anti-bribery, anti-corruption, anti-unfair competition, trade secrets, conflict of interest, and anti-money laundering, and requires suppliers to sign the Partner Code of Conduct《合作夥伴行為準則》together with the contract.

In 2024, the Group had no cases involving corruption.

Information security and privacy protection

Ocumension strictly complies with the laws and regulations like the Cybersecurity Law of the People's Republic of China《中華人民共和國網絡安全法》and the Personal Information Protection Law of the People's Republic of China《中華人民共和國個人信息保護法》, and have formulated the Provision of Management Information Systems《信息系統管理規定》and the Electronic Equipment Management Regulations《電子設備管理規定》the and the Management Procedures of Data Backup and Recovery《數據備份及恢復管理規程》and the Management Procedures for Data Server and Server Room《數據服務器和機房管理規程》, optimize the configuration and use of electronic equipment and software and avoid losses to the employee or the Group due to improper use to safeguard the Company's information security. In addition, strict requirements on information security and confidentiality are stipulated in the Compliance Manual《合規手冊》and the Employee Handbook《員工手冊》. In 2024, we revised the Information Security and Confidentiality Guidelines《信息安全與保密準則》, optimized the license management mechanism for the heads of direct departments, refined the requirements for localized management of electronic confidential data, and developed an electronic information system. These efforts can ensure that all documents are recorded as they are generated, thereby preventing information leakage. We also took a number of measures to fully protect personal information and privacy.

Permissions are arranged for top-secret information such as the company's important plans, confidential information, and the Group's financial statements to ensure that only authorised personnel can access it.

For the collection and utilisation of personal information related to employees, patients, medical professionals, customers and contractors involved in the course of business, we will handle it with care in accordance with relevant national laws and regulations, social concepts and internal rules and regulations of the Group to avoid information leakage or illegal use.

For trade secrets, we sign with employees the Non-Disclosure Agreement《保 密 協 議》and relevant confidentiality commitments, confidentiality guarantees or confidentiality declarations and other documents according to work needs.

Information system management personnel conduct annual inspections of information technology security in various departments, including whether there are any hidden risks in the local area network, whether user password settings are following the regulations, etc. In addition, information system management personnel are responsible for the supervision, data backup, virus prevention, and physical security of network and software systems within the Group to eliminate safety hazards. Meanwhile, we set the file server's three-level authorisation of read-only, read-write, and administrator to improve the efficiency of corporate file management while ensuring security. We also seek to safeguard the integrity and confidentiality of our data and trade secrets by maintaining the physical security of our premises, and the physical and electronic security of our information technology systems. In 2024, we strengthened our data security management by introducing a VPN access system and a bastion host system. We regularly drill for data disaster backup and restoration every year to prevent business interruption caused by major system problems. During the Reporting Period, we organized 1 drill for data disaster backup and restoration.

Meanwhile, we enhance the awareness of information protection and reduce the risk of information leakage by conducting training on information security and privacy protection. In 2024, Ocumension conducted 1 IT training session for all employees and 4 IT training sessions for new employees, covering the importance of information security, common information security threats, information security preventive measures, and case studies.

R&D Innovation for Health Accessibility

Contribution to the SDGs

Ocumension is committed to providing Chinese ophthalmic patients with excellent and comprehensive treatment solutions through continuous scientific research and innovation. We vigorously leverage years of experience in the ophthalmic field to explore, identify, develop, produce and acquire ophthalmic medicines. In addition, we are committed to the well-being of ophthalmic patients and their accessibility to optimal healthcare by building a responsible supply chain, conducting full lifecycle management of products and offering premium products and services.

Health accessibility

With the responsibility of "guarding vision, restoring colour sensation, and preventing colours from becoming memories", we are committed to building a comprehensive drug portfolio for the treatment of major ophthalmic diseases by pursuing dual-source innovation strategies through authorised introduction/acquisition or internal R&D. We strive to develop, manufacture and commercialize innovative quality products and leading treatments for Chinese patients with eye diseases.

- Independent R&D
  ——Research on new mechanisms
  ——Improye the use and compositions of drugs
- Authorised introduction
  ——The pioneered and best drugs of their kinds

Dual-Source Innovation

Registration and Development

- Optimised and innovative registration processes
  ——Approved new drug marketing application based on Real World Research data

Efhcient and excellent development strategy

- ——Apply for a clinical trial waiver and pnonity revew
  ——Accelerate clinical approval witn bridging trials

- Mature commercial platform
  ——KOL network
  ——Global business development capabilities
  ——Continuously expanding sales tearns
- Innovative and outstanding marketing strategies

Commereiali sation

Production and Manufacturing

- The production site has officially commercialized production
  ——Independently developed and licensed products are available
  ——Mass production of high-standard products by automated intelligent equipments

Responsible supply chain

The Group is devoted to building a more stable supply chain and ensure that cooperative projects are conducted in a compliant and productive manner. We has formulated the Procurement Management Regulations 《采購管理規定》, the Supplier Library Management Regulations《供應商庫管理規定》 and the Provisions on Factory Supplier Management 《工廠供應商管理規定》 to impose standardised requirements on suppliers and the entire procurement process. Meanwhile,we formulated the Stakeholder Management Procedures《相關方管理規程》to govern the environmental, health and safety management of external stakeholders for a responsible supply chain.

Our Supplier Management Committee is composed of the Group's Chief Executive Officer, Manufacturing Headquarters, Commercial Headquarters, Talent Development Headquarters and other departments, responsible for approving the preferred suppliers and implementing different management strategies according to the supplier classification. Our Purchasing Manager is responsible for all operations involved in supplier development, access and management.

When selecting suppliers, we demand evidence-based, transparent processes, avoidance of subjectivity and potential conflict of interest. We consider product quality, industrial reputation, innovation ability, compliance and risk control and other factors. All suppliers must meet the supplier access requirements and provide business licenses, qualification certificates, and other access materials before they can be added to the Ocumension supplier pool. We assess and score suppliers, conducting a series of online reviews to ensure that suppliers are selected fairly, objectively, and comprehensively. During the Reporting Period, we audited a total of 129 newly-developed suppliers on their qualification.

We conduct routine evaluations and annual performance assessments of our suppliers every year. Suppliers that have problems in quality, price, delivery period or service are required to implement corrective measures promptly on time and pass the supervision and inspection of the Group. During the inspection period, suppliers that fail to contract any business for 6 consecutive months will be put on the unqualified list. We conduct regular reviews of our suppliers, the frequency of which is determined by the type of purchases made, thus enabling effective and comprehensive supply chain management. We initiate on-site audits immediately when there are any quality issues with critical materials or when there are significant changes to key factors that may affect quality, such as production conditions, processes, quality standards, and inspection methods. During the Reporting Period, we conducted on-site audits of 33 suppliers and all of them were qualified.

The Group also pays attention to the performance of suppliers in terms of environmental protection and social responsibility and continuously strengthens the management of the suppliers' environmental and social responsibilities. We also pay attention to the environmental and social performance of suppliers in supplier access, daily management and audit, and remove suppliers that are implicated in major environmental accidents, use of child labour, and forced labour. In addition, we demand our suppliers to provide materials that comply with environmental requirements to ensure a sustained and stable supply of environmentally compliant materials, mitigating the negative environmental impact of the materials. We have established a closed-loop management mechanism for environmental, health and safety (EHS) issues of suppliers. With the mechanism, we assess the EHS performance of key and important suppliers by means of questionnaires, carry out on-site audits according to suppliers' EHS management, and follow up their corrective measures.

We conduct annual supply chain risk assessments to maintain the stability of our supply chain. During the Reporting Period, we identified risk factors such as regional conflicts and single sourcing. Accordingly, we responded proactively to these risks and assured stable supply by such means as centralized purchasing and developing alternative suppliers.

Number of suppliers by geographical region

Hong Kong, Macao and Taiwan **20**

Overseas **29**



Mainland China **1,055**

As of the end of Reporting Period, we had **1,104** suppliers, including **1,055** suppliers in mainland China, mainly located in Shanghai, Beijing, Jiangsu, and Zhejiang.

Full life-cycle management

Ocumension has been focused on building an ophthalmic platform that integrates professional capabilities in the full cycle of ophthalmic drug development from R&D, production to commercialisation. Strictly adhering to the Pharmaceutical Administration Law of the People's Republic of China《中華人民共和國藥品管理法》, Good Clinical Practice of Pharmaceutical Products《藥物臨床試驗質量管理規範》, Measures for the Administration of Drug Registration《藥品註冊管理辦法》, and other laws and regulations on various quality control measures, we have formulated the Quality Manual《質量手冊》, the Quality Risk Management Protocol 《質量風險管理規程》 and other institutional documents to manage the entire life cycle of R&D, clinical trial, registration, production and sales of pharmaceuticals, ensuring that medicines are safe, effective and of controllable quality.

We are committed to establishing and developing fully integrated R&D capabilities, using them as an internal engine to promote our agenda of discovering, developing, and commercialising the most innovative and best-in-class treatments for patients with eye diseases in China. As of the end of the Reporting Period, our R&D team comprised 57 members, 4 of whom held medical doctorates and 34 of whom held master's degrees. The members possessed a full range of capabilities and multidisciplinary backgrounds from processes like the discovery of new medicine and preclinical studies to clinical trials and extensive professional knowledge in the fields of pharmacology, toxicology, traditional medicine and chemistry, and many members have more than 10 years of experience in the field of ophthalmology.

R&D team comprised **57** members

4 of whom held medical doctorates

34 of whom held master's degrees

Drug development

In the product design and R&D phase, we uphold the concept of Quality by Design (QbD). Based on a full understanding of the Quality Target Product Profile (QTPP) and Critical Quality Attributes (CQAs), integrating all key process parameters and the range of key process parameters involved in CQAs, to strengthen the understanding of and control over the pharmaceutical process and ensure continuous control over product quality.

We have owned an advanced Chemical, Manufacturing and Control (CMC) research laboratory to develop innovative and generic ophthalmic drugs, such as sterile solutions, gel suspensions, nano or microemulsions, etc. Our laboratory in the Suzhou manufacturing plant with above 100 world-class precision instruments (including such preparation equipment as small filling machines, ultrasonic generators and stirrers and such analytical instruments as high performance liquid chromatograph, gas chromatography and Malvern mastersizer.) and advanced scientific data management systems to enhance our pharmaceutical R&D capabilities and guarantee data reliability and traceability.

Liquid phase chamber

High temperature chamber

In the pre-clinical research phase of drugs, we strictly abide by the Regulations for the Administration of Affairs Concerning Experimental Animals 《中華人民共和國實驗動物管理條例》and other laws and regulations regarding experimental animals, adhere to high standards of ethical practice and scientific behavior in all experiments, and ensure that all work is done in compliance with relevant R&D ethics and animal ethics policies through monitoring and recording.

We know that strengthening the refined management of IP, controlling potential IP risks, and safeguarding the legitimate rights and interests of intangible assets are the basis for nurturing core competitiveness. In our Compliance Manual《合規手冊》, we have made detailed provisions on the ownership, transfer, application, filing, transfer and use of IP to enhance systematic IP protection. Where the Group's IP is infringed, the Group will take timely action to redrive IP protection through submission of objections, filing of lawsuits and other methods. As of the end of the Reporting Period, the Group has registered 268 trademarks and owned 48 patents.



Clinical research and development

We have established a complete clinical R&D platform built with functions of clinical research and medical, clinical project management, data management and biostatistics, pharmacovigilance, etc., covering the entire clinical process from phase I to phase III and the Real World Research. For each clinical development project, we designate a project manager to formulate clinical development plans, design experimental plans, and supervise trial execution with project team members. To ensure the quality and efficiency of clinical trials, we also engage leading professional Contract Research Organizations (CROs) to conduct daily management and execution of clinical trials. In addition, we have developed a quality control system for clinical R&D focusing on quality and established a standard procedure to ensure clinical trials are effective, and formed a clinical research quality control team with members from various departments such as medicine, operations and pharmacovigilance for regular quality supervision and management of clinical trials.

To expand the scope and efficiency of our clinical trials, we collaborated with industry-leading research organizations to manage, conduct and support our pre-clinical studies and clinical trials. For the selection of CROs, we follow strict audit standards to assess them from their professional qualifications, research experience, industry reputation, adequacy of clinical trial equipment, and data management systems, etc. Further, we will sign a cooperation agreement with the CRO and reach agreements in terms of service, time limit, payment, IP and risk allocation.

In order to ensure the safety of clinical trials, we strictly implement the Good Clinical Practice《藥物臨床試驗質量管理規範》and other related requirements, and set up a post of pharmacovigilance specialist to be responsible for the monitoring, collection, analysis, investigation and reporting of all adverse drug reactions, and to cooperate with drug administration agency to conduct investigations. Our clinical teams communicate with contracted research organizations regarding adverse events in a timely manner during clinical trials. Our pharmacovigilance escalation system covers the entire pharmacovigilance workflow across the entire pharmaceutical lifecycle. At the same time, we ensure that our subjects' rights and interests are well protected by means of informed consent, regular reports of adverse reactions, purchase of patient insurance, and free drug treatment.

We attach importance to the capacity building of the clinical team and carry out various internal communication and training activities at the project and department levels, such as clinic research-related training, monthly clinical R&D meetings, etc., to ensure full coverage of clinical R&D staff. In addition, we encourage clinical R&D personnel to participate in external exchanges or professional vocational training activities. During the Reporting Period, we invited external lecturers to conduct training on themes such as the Quality Management and Verification Response and the On-Site Inspection of Clinical Trials, which included the quality requirements in clinical trials under new regulations, supplier screening and management, and how to respond to on-site inspection. In addition, we also actively participated in external training and seminars, including clinical trial project management at DIA 2024 and special training on the registration application of new drugs under the new situation, to keep abreast of the latest laws and regulations, as well as the cutting-edge technology, and to enhance our professional competence.

Product registration

We strictly comply with Measures for the Administration of Drug Registration 《藥品註冊管理辦法》 and take initiative in understanding the registration practices of regulatory bodies and communicate with the relevant regulator on the approval of new drugs for clinical research. We are committed to promoting the commercialisation of our drug candidates in China with maximum efficiency, using our extensive regulatory, commercial expertise, and the best regulatory channels.

To ensure that the Group's product R&D and registration is carried out in a standardized and orderly manner, we have established the R&D Registration Committee. The committee discusses and resolves principle issues arising from the formulation of the overall R&D plan, the development strategies and plans for each R&D product, as well as any principle issues encountered during implementation. Additionally, it serves as a cross-departmental communication platform to address horizontal issues. Additionally, we have formulated and improved the Drug and Medical Device Registration Application Data Management System《藥品和醫療器械注册申請資料管理制度》and the Drug and Medical Device Registration Approval File Management System《藥品和醫療器械注册批准檔管理制度》. These systems ensure that the registration of drugs and medical devices remains complete and continuous throughout their life cycle and complies with the requirements of relevant laws and regulations.

Production of products

With the quality policy of Quality Focus, Continuous Improvement, Pursuit of Excellence, we have put in place a quality management system for outsourced production, self-production and commissioned production according to the regulatory laws and regulations, and relevant requirements of Good Manufacture Practice (GMP) for Pharmaceutical Products of the regions where the products are marketed, and formulated specific quality plans and targets. In 2024, we met our quality goals successfully.

Ocumension's quality goals

- **100%** pass rate for internal quality sampling
- **100%** pass rate for market supervisory sampling
- Complaint rate of product quality **≤0.5%**
- **100%** satisfaction rate for handling customer complaints
- **0** product recall
- **0** quality incident

The quality director of the Group, the head of quality assurance in the Suzhou manufacturing plant and the quality authorized person are responsible for establishing and optimising the Group's drug quality management system. They organise internal and external quality audits and management reviews to ensure the effective operation of the above system. Besides, they strictly abide by laws and regulations on drug quality management, standardise quality management during drug production, and assume such responsibilities as product release. The Group's production director and head of production management are in full charge of production arrangement. As an effort to guarantee the product quality, they must organise production and storage in accordance with the approved processes, conduct necessary verification, and ensure that production personnel are qualified for the job after training and that the production process complies with the requirements of GMP.

To effectively improve the quality management system and enhance the quality of Ocumension's products, we upgraded the Quality Committee to a quality analysis meeting in 2024,which is carried out once a month. The meeting is attended by the Company's legal representative, production leader, quality leader, pharmacovigilance leader, the quality authorized person, heads of various departments, and heads of various offices. The meeting focuses on analyzing compliance risks, product quality risks and quality system risks. Moreover, we organize a separate quality open day communication meeting for each department such as the production department, the quality department, the engineering department, and the general affair department every month to collect suggestions or problems on quality management for rectification and implementation. In addition, in 2024, the quality department carried out on-site inspections of various departments including the production department, the engineering department, as well as warehouse and laboratories. For any issues identified during these inspections, the relevant departments were required to list the root causes, rectification measures, responsible persons, and completion time. The quality department then tracked and confirmed the completion of rectification, and the inspection results were linked to the KPIs of relevant departments in the GMP assessment to further ensure the routine management of GMP. During the Reporting Period, we conducted a total of 4 external quality audits and 2 internal quality audits. All identified deficiencies were rectified.

As of the end of the Reporting Period, our Suzhou manufacturing plant was designed in line with Chinese, US and EU standards for quality management practices in pharmaceutical manufacturing and has been granted type A, B and C pharmaceutical manufacturing licenses in China and GMP Certification.

We kept improving the Manufacturing Execution System (MES) to realize full process traceability for materials. Digital material approval records are generated in accordance with industry regulations and relevant workstation operating procedures, which ensured real-time and effective quality management. We are taking steady steps to achieve automated, digitalised and paperless plant operation for higher production efficiency. For product packaging, we have established the Management Regulations for Inner Packaging Materials and Printing Packaging Materials《內包裝材料及印刷包裝材料管理規程》to guide the management of the entire process from design to use of internal and external packaging materials, to avoid misuse of packaging materials or mislabeled information. During the Reporting Period, we carried out lean production programs, and collected a total of 11 lean production topics, including optimization of sampling and inspection processes for outsourced materials, optimization of cultivation methods for environmental monitoring petri dishes, and integrated production. These initiatives effectively enhanced production efficiency, reduced losses, improved accuracy and lowered costs.

We have instituted a comprehensive quality training management system, developed the Training Management Procedures《培 訓 管 理 規 程》to standardise the design, management and implementation of quality training. and conducted non-scheduled quality training and job training assessments to raise the quality awareness of staff, to ensure that they are capable of performing their tasks in line with the GMP requirements. During the Reporting Period, we conducted 14 company-level quality trainings, covering topics such as the Supervision Measures for Drug Production, the Good Manufacture Practice (GMP) for Pharmaceutical Products, the Quality System, the BFS Aseptic Filling Technology and the Basic Knowledge of Microbiology. A total of over 1,500 participants attended these training sessions. Additionally, we conducted more than 200 department-level training sessions. In doing so,our employees whether from the quality department or from other departments in the Group became more competent both professionally and technically. In 2024, we launched the activity of the One Regulation-related Question One Day,in which we posed a question related to current drug management each day and required all employees to participate. We summarized and publicized the participation and accuracy rates of each department on a weekly basis. This activity reinforced employees' understanding of pharmaceutical production regulations and fostered a learning atmosphere. Furthermore, we applied the online TMS system for training management, to comprehensively manage the quality training in terms of instructors, courseware,quizzes,training matrix and positions/personnel.This ensured that all training sessions were completed in time.

BFS aseptic filling technology training

Client service

We have obtained the certificate of Good Supply Practice for Pharmaceutical Products (GSP) and have carried out quality control over the entire process of pharmaceutical operation from the procurement, acceptance, storage, sales, and after-sales service of drugs to ensure the provision of quality medicines to customers.

We strengthened our contacts with customers through various marketing activities. By using the WeChat platform “Easy Vision” and “Ocumension herapeutics”, we carried out doctor training and patient education, further promoting our products.

Customer management

Further improve the customer management system by optimising the treatment concept of doctor customers and refining the classfication of doctor customers.

Customer training

Establish a complete series of training on standardised diagnosis and treatment for doctors, which considers both common knowledge and individual needs to train more professional doctors in the field of uveitis and promote industry standardisation.

Patient education

Refine the popular science education for patients, and explore more educational channels such as short video platforms to convey the concept of patient carel.

To better manage customer relationships and increase customer satisfaction for sustainable corporate development, we launched the CRM system. The system enables information sharing and analysis across departments within the Company and assists business divisions in fully understanding customer demands and market trends to optimise their service strategies.

1 Responsible marketing

The Group strictly complies with relevant laws and regulations such as the Advertising Law of the People's Republic of China《中華人民共和國廣告法》, the Interim Measures for the Examination and Administration of Advertisements of Drugs, Medical Devices, Health Food and Formula Foods for Special Medical Purposes《藥品、醫療器械、保健食品、特殊醫學用途配方食品廣告審查管理暫行辦法》and refers to the RDPAC Code of Practice 《RDPAC行業行為準則》 issued by the R&D-based Pharmaceutical Association Committee, China Association of Enterprises with Foreign Investment (RDPAC), and formulated the rules and regulations such as the Guidelines for the Promotion of Pharmaceutical Products《藥品推廣準則》, the Provisions for the Promotion of Pharmaceutical Materials《藥品宣傳資料規定》, the Regulations on the Release of Company Publicity Materials《對外發佈公司宣傳資料規定》, thus carrying out strict control over the marketing information published by various channel and ensuring the accuracy of marketing content.

All drug publicity materials shall be submitted through internal systems and reviewed by the Marketing Department, Clinical Research and Development Department, Legal & Compliance Department, etc. It needs to confirm that exaggerative, assertive or other expressions that violate the relevant provisions of the Advertising Law of the People's Republic of China 《中華人民共和國廣告法》and contents of suspected fraud and inducement are not used, before they can be produced and used for publicity. We have strict codes of conduct for our sales and marketing staff and provide Regular compliance marketing trainings to keep the staff informed of the latest relevant laws, regulations and policy requirements.

2 Complaints and recalls

We have formulated User Complaint Feedback and Handling Procedures 《用戶投訴回饋及處理規程》 to standardize produce complaint handling process, evaluate complaints and track the whole process. We categorise the clinical complaints, pharmacy complaints, and commercial complaints on Ocumension's products and agency products into serious user complaints, important user complaints and general user complaints according to their severity. All complaints received should be registered in a timely manner and handled by the Quality Department, which will require relevant responsible departments to make effective rectifications according to the investigation and handling process. If necessary, we will promptly notify the regulatory authorities. During the Reporting Period, the Group didn't receive any customer complaints regarding our products.

We strictly comply with the Administrative Measures for Drug Recalls 《藥品召回管理辦法》and the Good Manufacture Practice for Pharmaceutical Products《藥品生產質量管理規範》, and have set up the Product Recall Management Regulations《產品召回管理規程》to standardize the workflow of product recall and ensure that products can be promptly and comprehensively recalled in case of quality problems or forced recalls, to safeguard the health and life safety of patients. According to the level of product safety risks and hazards, the recall of medicines is categorised into three levels. In detail, within 24 hours for level one recalls, 48 hours for level two recalls, and 72 hours for level three recalls, the notification of the recall shall be issued to the relevant distributors and end users to stop the sale and use of recalled products. After initiating medicine recalls, in the first level, drugs shall be recalled within 1 day, the second level within 3 days, and the third level within 7 days. The Group will submit the Medicine Safety Hazard Investigation and Assessment Report and the Product Recall Plan to the drug administration agency for documentation. When there is no product recall, we conduct a simulated recall every 3 years to examine the effectiveness of the recall process. During the Reporting Period, the Group had no product recalls due to safety and health reasons.

Diversity and Inclusion for Employee Development

Contribution to the SDGs

Employees are our most valuable asset. We respect and value every employee and have continuously improved our employment management system to comprehensively safeguard the rights and interests of our employees. We are committed to building an employment partnership with mutual growth and success, and we build an equal, inclusive and harmonious career development platform, while constantly improving occupational health and safety management and the happiness index of our employees. By doing so, we help our employees to make their careers. We are also committed to creating a work environment full of respect, inclusion and opportunities to attract and retain outstanding talents and create a better future together.

Compliance employment

Ocumension always follows the principle of legal compliance in employment and strictly abides by and implements relevant laws and regulations such as the Labour Law of the People's Republic of China《中華人民共和國勞動法》, the Labour Contract Law of the People's Republic of China《中華人民共和國勞動合同法》, the Provisions on the Prohibition of Using Child Labour《禁止使用童工規定》, and has formulated the Employee Handbook《員工手冊》to protect the rights and interests of its employees in concrete actions.

Ocumension values labor rights, prohibits the use of child labour and forced labour. We authenticate the identity of candidates by collecting compliance information and signing employment contracts in line with legal standards with all employees to eliminate any employment of child labour and forced labour. In the event of the employment of child labour or forced labour, the Group will conduct an investigation in accordance with established procedures. Once any violation of the law is confirmed, it will be handed over to the relevant judicial authority, and we will terminate the labour contract. During the Reporting Period, the Group had no violations involving child labour or forced labour.

Ocumension advocates a diverse and inclusive corporate culture, ensuring that employment and career development opportunities for the employees are not undermined by factors such as age, gender, geographical location or appearance. We have set up diversified recruitment methods such as campus recruitment, online recruitment and social recruitment to cover a wider variety of talents. In the training and promotion process, we treat every employee fairly and equitably to ensure that every employee can make their career in an inclusive, diversified and harmonious culture. We are committed to providing an equal, respectful, and equal opportunity working environment for our employees, where every employee can fully unleash their potential and achieve personal value and career growth. In 2024, we were honored with multiple Best Employer awards.

Ocumension was honored with the title of 2024 Greater Suzhou Best Employer and the title of Top Ten Employers in Wuzhong District.

As of 31 December 2024, the Group employs **489** people, all of whom are full-time employees, of which **47.4%** were female.

Total workforce by gender (Unit: person)



Total workforce by age group (Unit: person)



Total workforce by geographical region (Unit: person)



Total workforce by educational background (Unit: person)



The turnover procedures are followed in strict accordance with labour contracts and laws and regulations. During the Reporting Period, the Group's turnover rate was **14.9%**.



Compensation and benefits

Compensation composition

In consideration of "responsibilities and performance, personal abilities, and in line with external market levels", we constantly improve our remuneration structure, optimized the Measures on Remuneration Management《薪酬管理辦法》to provide our employees with attractive emoluments and benefits in the market.



Employee incentive plan

Ocumension offers a comprehensive employee incentive plan for its employees. In order to encourage employees to stick to their posts and actively participate in various important activities and projects for the development of the Group. We have formulated the Implementation Plan for the CEO Special Contribution Award《CEO特別貢獻獎勵實施方案》 and established the CEO Special Contribution Award to reward employees who have made outstanding contributions to the company's business development, management optimization and innovation, brand enhancement, and other aspects. In 2024, we have awarded 3 CEO Special Contribution Awards, 1 Golden Owl Award, and 2 Silver Owl Awards. Ocumension awards all eligible employees based on its share option scheme for employees to further attract, motivate, and retain talents.

Working hours and leaves

Ocumension strictly abides by legal regulations and have formulated the Leave Management System《假期管理制度》to protect the employees'right to leave. Employees of the Group enjoy a variety of holidays such as weekends, national holidays, paid annual leave, marriage leave, maternity leave, and home leave, etc. To improve employees' work efficiency in a fairer way, we updated the Overtime Policy《加班政策》during the Reporting Period, by adjusting the position scope under the working hour system and the minimum unit for compensatory leave. Our group does not encourage overtime work. If overtime is required based on business conditions, employees shall submit a written application letter for overtime, and they can apply for compensatory leave or receive overtime pay as appropriate.

We not only focus on our employees' work performance, but also value their personal well-being and quality of life. Apart from work, we foster a comfortable and welcoming working environment through a wide variety of employee activities to significantly make our employees happier. In today's fast-paced living environment, we also attach great importance to employees' mental health. During the Reporting Period, we established the Captain's Worry-Free Station, which provides free EAP psychological counseling services to all regular employees and their immediate family members.

During the Reporting Period, we organized a variety of activities such as employee birthday party to provide employees with opportunities to relax themselves and enhance communication. These activities helped to strengthen team cohesion and enhance employees' sense of well-being and belonging.

Employee birthday party

Gifts for Women's Day

Christmas gifts

Employee communication

As employee voice matters, we collect our employees' reasonable suggestions and opinions in various ways, such as Direct Communication with the General Manager, youth forum and satisfaction surveys.

Direct Communication with the General Manager

Direct Communication with the General Manager covers all employees. Every employee can anonymously communicate with the CEO at zero distance. After the communication, the matters of concern are fed back to all employees via email with immediate rectifications.

Satisfaction survey

We regularly conduct employee satisfaction surveys to collect feedback on the working environment. During the Reporting Period, we launched a special satisfaction survey on work meals and made improvements based on employees' feedback.

Collection of reasonable suggestions

We actively listen to our employees and give feedback on all of their improvement suggestions. We adopt excellent improvement suggestions to continuously improve the working conditions of our employees. During the Reporting Period, a total of 74 reasonable suggestions were received and 48 were adopted.

Health and safety

Ocumension pays great attention to the occupational health and safety of our employees. We strictly abide by laws and regulations such as the Labour Law of the People's Republic of China《中華人民共和國勞動法》, the Work Safety Law of the People's Republic of China《中華人民共和國安全生產法》, and the Law of the People's Republic of China on the Prevention and Control of Occupational Diseases《中華人民共和國職業病防治法》. We have established a comprehensive EHS management system and formulated internal management systems such as the EHS Goal Indicators and Assessment Management Procedures《EHS 目標指標和考核管理規程》, the Project EHS Management Regulations《項目 EHS 管理規程》and the EHS Performance Assessment Plan《EHS 績效考核方案》. The Group has established an EHS Committee at our Suzhou manufacturing plant for decision-making on major safety matters and approval of critical EHS documents. The Group puts forward the requirements of EHS full life-cycle management, specifies the requirements for the annual EHS goal assessment and for the supervisory assessment of daily management. These requirements are included in the personal performance assessment of all employees in the factory. We promote full participation in safety management work, continuously improve the EHS management system, and prevent and eliminate major safety risks from the source.

With a sound governance structure and oversight from senior management, we take concrete actions to ensure effective health and safety management across Ocumension. During the Reporting Period, we obtained the ISO 45001 Occupational Health and Safety Management System Certification and the Advanced Unit Certificate for Safety Management of Hazardous Chemicals in Suzhou in 2023.

We continue to optimize the assessment of machinery safety and the management of safety facilities, and enhance the safety of our work environment from dimensions of occupational health and safety, hazardous chemical protection, special equipment management, and emergency preparedness. In 2024, we further updated the Occupational Health Management Regulations《職業健康管理規程》, adding requirements for special substances and highly active and toxic drugs in health protection assessment and grading of occupational exposure banding (OEB). We also clarified engineering prevention and control strategies and personal protective equipment strategies to ensure the heath of operators when they expose to special substances and highly active and toxic drugs. Additionally, we refined the Management Regulations on Personal Protective Equipment 《個人防護用品管理規程》, the Management Regulations on Production Safety Investment《安全生產投入管理規程》and other policies. We established requirements for regular assessment, selection, distribution registration, use and maintenance of protective equipment, as well as management requirements for production safety investment. We regularly conduct comprehensive EHS risk assessment every year and develop appropriate control measures based on the assessment results. So far, we have completed 17 assessments of Failure Mode and Effects Analysis (FMEA) for facility and equipment systems, evaluated over 700 equipment functions/-components, and put forward more than 60 improvement suggestions.


bsi.

Certificate of Registration

职业健康安全管理体系 - ISO 45001:2018

OHS 784749

...making excellence a habit.

ISO 45001 Occupational Health and Safety Management System Certification

Advanced Unit for Safety Management of Hazardous Chemicals in Suzhou in 2023

Security risk assessment

The Group has formulated the Management Procedures for Hazard Source Identification and Risk Evaluation《危險源辨識、風險評價管理規程》 and established a clear procedure for identifying, evaluating and taking effective control measures.

The Group conducts risk identification and hazard source identification for occupational health and safety on a regular basis to mitigate the risk of safety accidents and exposure to occupational health risks.

The Group regularly engages third-party professional institutions to conduct testing for occupational hazard factors and issue testing reports.

Safety assurance

The Group conducts safety inspection activities on a regular basis. In 2024, a total of 49 potential hazards were identified through the monthly inspections by the Group's Safety Committee and weekly EHS inspections, and all have been rectified.

The Group provides employees with protective equipment such as protective gloves, protective glasses, safety shoes, insulating boots, and protective face shields to ensure their safety during work operations.

The Group consistently arranges health check-ups for all employees, with all costs borne by the Group.

Hazardous Chemicals

The Group has improved the Chemical Management Regulations《化學品管理規程》to mitigate the environmental impact and occupational health and safety risks of the chemicals.

The Group assesses existing and new chemicals and rectifies any non-compliance with environmental emission, industrial hygiene and occupational health requirements on site.

All new employees are required to receive professional training prior to accessing and handling hazardous chemicals. The employees also receive annual chemical training and hazard training.

Special Equipment

The Suzhou manufacturing plant has established a special equipment management team for Ocumension's special equipment. The tasks of the team include regular annual inspections, annual inspection of safety accessories, preparation and maintenance of technical files, supervision of special equipment maintenance and accident management of special equipment.

The supervisors and operators of special equipment must be 100% certified, whose scanned copies should be archived by the EHS management department for future reference.

Emergency Response Management

The Group has perfected the Emergency Response Management Regulations《應急響應管理規程》to ensure "always ready, prompt action and solid protection"against any emergencies.

The Group has established an emergency response team. The team attends regular training on emergency response organised by Ocumension as well as formulates emergency rescue plans and completes preparations for drills.

EHS culture development

The Group stresses the importance of "Observing the Work Safety Law of the People's Republic of China and Acting as the Person Primarily Responsible for Work Safety", continuously enhancing employees' safety awareness and emergency response capabilities.

The Group conducts a series of training and awareness promotion activities for employees through offline training and online learning platforms. Participants are required to pass relevant examinations to guarantee the effectiveness of the training. In 2024, a total of 37 plant-level EHS training sessions and 36 department-level EHS training sessions were conducted, with a total of 13,350 participants.

The Group organizes multiple drill activities, including hazardous waste leakage drills, plant-wide fire evacuation drills, and a series of activities for the work safety month.

From the date of incorporation to the end of the Reporting Period, there was no work-related fatality. In 2024, the Group lost 15 working days due to work-related injuries and there were no major safety accidents or occupational disease incidents.

Fire fighting drills

Leak response drills

First aid training

First aid training

Case

First Aid Knowledge Training

In 2024, Ocumension organized 4 training activities on common first aid knowledge (3 in Suzhou factory and 1 in Shanghai office), with a total of 174 colleagues participating. The training integrates theoretical explanations with on-site practices, covering a range of topics such as cardiopulmonary resuscitation, the Heimlich maneuver, wound dressing, hemorrhage control, and outdoor first aid methods, as well as the use of first aid kits. This training demonstrated Ocumension's strong commitment to the personal safety of its employees.

Selection of outstanding cases for on-site emergency response drills targeting sudden accidents

Case

Work Safety Month Activities

During the work safety month, we organized a selection event for outstanding cases of on-site emergency response drills targeting sudden accidents. Departments and offices actively established teams to simulate on-site emergency response drills based on potential accident scenarios they might face. Through this process, each team enhanced its ability to respond to emergencies and accumulated valuable practical experience. After the drills, we carried out a rigorous evaluation and selected a series of outstanding cases, providing valuable references for our future emergency management.

Development and training

Adhering to the belief that employees are our most valuable asset, Ocumension always regards the mutual development of the enterprise and its employees as one of its key responsibilities. We are dedicated to providing our employees with comprehensive and systematic training and development plans. We have formulated the Post Management Measures 《岗位管理辦法》 and the Annual Promotion Policy 《年度晉升制度》 to refine the employee development system and encourage employees to improve their quality and ability. Meanwhile, we have established diversified promotion channels and a constraint mechanism to demote and promote employees based on their performance, with the intention to develop clear career paths for employees based on scientific analysis.

Ocumension's internal positions are divided into professional sequence and management sequence according to the characteristics of different jobs. The professional sequence is further divided into sales sequence, R&D sequence, support sequence and manufacturing sequence according to the characteristics of the specific expertise. Based on the degree of post contribution, posts rank from level 1 to level 50, and employees are rewarded according to their performance, ability, and contribution to the business.

To help employees continuously improve their professional skills, expand their knowledge horizons, and achieve sustained progress in their careers, we continue to refine our training system, providing employees with formal and comprehensive orientation and daily training.

Panda Project

Senior employees are encouraged to establish learning partnerships with new employees. This helps new employees get fully familiar with their responsibilities, and encourages them to take an active part in the communication and collaboration between departments.

Dragon and Fish Training Program

This program provides employees with advanced training on the business of the Company and the work content and process of each department,thus facilitating our identification of high potential talents to efficiently build talent pool. In 2024, a total of 9 training sessions were conducted.

Management Academy program

This is a specialized training program tailored to cultivate management skills of management. In 2024, a total of 7 training sessions were conducted.

New recruit training

The new recruit training focuses on topics such as knowledge of common ophthalmic diseases, ophthalmic market conditions, product lines, therapeutic areas and effect mechanism of products, compliance requirements, and the Company's strategies.

Professional training

A number of online and offline training are carried out internally and externally on expertise about fundus diseases.

Other training

Through advanced training and external training, we ensure that employees are well-informed about the Company's policies and procedures, overall planning, various products, as well as the basic knowledge of ophthalmic diseases.

Management Academy training

Training on knowledge of ocular diseases for new employees in Guangdong, Guangxi and Hainan

In 2024

The training ratio of the employees of the Group was
100%

The total training hours for the year were
17,449 hours

The average training time was
35.7 hours per person

The percentage of employees trained by emoloyee category



The percentage of employees trained by gender



The average training hours completed per employee by employee category (Unit: hours/person)



The average training hours completed per employee by gender (Unit: hours/person)

Low-Carbon and Environmentally Friendly Practices for Green Development

Contribution to the SDGs

With a commitment to green and low-carbon operations, Ocumension always gives priority to environmental protection while developing its business. We have established a robust environmental management and energy management system to minimize resource consumption and enhance energy efficiency. This helps reduce environmental pollution, thereby contributing to the achievement of sustainable development.



Environmental management

Ocumension strictly complies with relevant laws and regulations such as the Environmental Protection Law of the People's Republic of China《中華人民共和國環境保護法》and the Energy Conservation Law of the People's Republic of China《中華人民共和國節約能源法》, and active response to the call of "embracing energy conservation, environmental protection, and low carbon". We have set environmental goals of improving resource use efficiency and reducing emission, to better perform our environmental protection responsibilities.

The Group has established an EHS Committee at Suzhou manufacturing plant, serving as the highest decision-making body for EHS matters within the Company. The committee is responsible for coordinating, guiding, and supervising important EHS issues across systems, functions, and departments in an integrated manner. The EHS Committee convenes monthly, quarterly, and annually to discuss past EHS performance and significant events, learn about new policies and regulations, grasp the Company's EHS development progress, and identify encountered issues and challenges. In addition, next steps and major EHS initiatives are formulated.



- Chair quarterly and annual Safety Committee meetings;
- Make decisions on and approvals for material issues and matters;
- Provide resource guarantees for the normal operation of the EHS Committee.

- Make decisions on material issues and matters;
- Report on departmental EHS work on a regular basis;
- Provide support for EHS management and coordinate EHS tasks;
- Communicate Safety Committee meeting requirements within the department.

- Have the right to suggest and propose material issues;
- Implement EHS work assigned by the Safety Committee;
- Provide support for EHS management and coordinate EHS tasks;
- Communicate Safety Committee meeting requirements within the department.

We have formulated and revised multiple EHS-related policies in light of its own condition, such as the EHS Management Manual《EHS管理手冊》, the Environment, Health and Safety Training Management Procedures《環境、健康和安全培訓管理規程》and the Laboratory EHS Management Procedures《實驗室EHS管理規程》. Furthermore, potential environmental impact factors are comprehensively identified and analyzed in a timely manner, and measures are taken to rectify any issues identified. During the Reporting Period, we identified a total of 230 environmental factors and 140 sources of environmental factors (activities, products, and operations), and formulated 23 control measures. We have established environmental protection ledgers and files, departments and individuals with outstanding achievements in environmental protection will be recognised and rewarded, and those who violate the regulations and cause environmental pollution accidents will take corresponding responsibilities.

To enhance our ability to prevent environmental risks, we have formulated the Emergency Response Plan for Environmental Emergencies《突發環境事件應急處理預案》. During the Reporting Period, we conducted emergency response drills for environmental emergencies, including specialized drills for hazardous waste and on-site disposal drills for liquid chemical leaks. These drills effectively reduced the harm caused by environmental emergencies.

The Group carries out internal and external audits for environmental management on a regular basis. The Suzhou manufacturing plant has obtained ISO 14001 Environmental Management System certification and successfully passed the review.


bsi.
Certificate of Registration

ISO 14001 Environmental Management System Certificate

With a keen focus on the cultivation of environmental protection awareness among employees, Ocumension has developed a detailed EHS training program. As part of the program, environmental protection training sessions are conducted on a regular basis, covering topics on EHS laws and regulations, hazardous wastes, identification of environmental factors, and environmental pollution and prevention. We launched a self-learning course of "EHS Column" on the online platforms, covering over 40 sessions of EHS related learning materials. Meanwhile, we have an incentive mechanism in place to motivate independent learning of employees by organising quarterly exams and granting rewards to those who excel in the exams. In 2024,we organized specialized EHS training at both the plant and department levels, covering all employees. The total number of trainees exceeded 13,000, with a total of nearly 2,000 training hours.

Resources management

Knowing that the world is facing a resource shortage, we are committed to promoting the concept of energy saving, emission reduction and water saving and taking various measures to strengthen the efficient use of resources. The Suzhou plant has set up an energy management structure and appointed an energy management team leader as well as its members. Additionally, energy management efforts are carried out in accordance with the ISO 50001 Energy Management System. Furthermore, we actively incorporate green energy into our operations. The rooftop of the Suzhou plant was paved with photovoltaic panels, with a model of "self-generation for self-consumption, with surplus electricity fed into the grid" to power the plant. The installed capacity reached 1.2MW.

In 2024
the photovoltaic power generation reached
1,260,429 kWh



Workplace

- To encourage employees to develop resource-saving habits, energy and water conservation campaigns have been conducted, and posters with reminders to save electricity and water have been put up.
- Formulate Regulations on Company Car《公司用車管理規範》to properly manage and allocate company cars as well as avoid wasting resources.
- The office air conditioning system adopts a centralized control for reasonable adjustment of ambient temperature, avoiding energy waste caused by forgetting to turn off.

Suzhou manufacturing plant

- Formulate the Management Procedures for Energy Consumption Control《能耗管控管理規程》and regularly check the use of lighting, air conditioning and tap water in the plant.
- Adopt the centralised control model for the clean area to remotely turn off workshop lighting.
- Use human sensing and voice-activated lights for personnel channels, stairways, toilets and other public areas to reduce energy waste.
- Utilise clean energy of photovoltaic power on rooftop.
- Use LED tubes for all lighting devices to reduce power consumption.
- Control the air conditioner automatically according to the room temperature.
- Equipped with a rainwater harvesting system, replace spray heads of stormwater tanks for greening irrigation.
- Replace disposable hats for workshop staff with reusable ones.
- The air conditioning in the power distribution room has been switched from direct start to variable frequency start.
- Filling-packaging production line has been integrated to improve production efficiency and reduce energy consumption.



Case

Optimization and Renovation of the Air Conditioning Cooling System in the Warehouse for Energy Saving and Consumption Reduction

To optimize energy usage in the plant for energy conservation and emission reduction, in 2024, we implemented a renovation of the air-conditioning cooling medium piping in the warehouse, enabling a switch between the ethylene glycol system and the cooling water system. Before the renovation, both the ethylene glycol system and the cooling water system units needed to be kept running continuously. After the renovation, during spring and autumn, the system can switch to the ethylene glycol system, allowing one cooling water unit to be shut down. This resulted in annual electricity savings of approximately 115,000 kWh, significantly reducing energy consumption.

In 2024, the Group's resource utilization KPIs are shown as follows：

Environmental KPIs[4]	Unit	2024	2023
Total energy consumption[1]	MWh	15,623.82	12,635.03
Total direct energy consumption	MWh	82.60	3,713.45
Including: Petrol	MWh	54.51	54.51
Including: Natural gas	MWh	28.10	3,658.94
Total indirect energy consumption	MWh	15,541.22	8,921.58
Including: Purchased electricity	MWh	6,552.80	5,593.29
Including: Purchased steam	MWh	8,988.42	3,328.30
Energy consumption intensity	MWh per million RMB revenue	37.44	51.29
Total water consumption[2]	tonne	70,782.80	54,647.80
Total water consumption intensity	tonne per million RMB revenue	169.62	221.81
Total packaging material used for finished products[3]	tonne	15.61	/
Intensity of packaging material used for finished products intensity	tonne per million RMB revenue	0.04	/

Notes：

1.Total energy consumption is calculated based on the consumptions of electricity and fuel and the default parameter values related to common fossil fuel characteristics as shown in Attached Table 2 to Guidelines for Accounting and Reporting Greenhouse Gas Emissions of Other Industrial Enterprises《工業其他行業企業溫室氣體排放核算方法與報告指南》issued by the National Development and Reform Commission (NDRC).

2.The Group's water consumption is mainly for domestic use and sourced from the municipal water system, which is sufficient for daily operation.

3.In 2024, the Group officially commenced in-house pharmaceutical production, leading to the inclusion of KPI A2.5 (Total packaging material used for finished products and with reference to per unit produced) in our disclosures.

4.In 2024, the Group officially commenced in-house pharmaceutical production, leading to a significant increase in the total indirect energy consumption and water consumption.

Emissions management

Ocumension strictly comply with laws and regulations such as the Environmental Protection Law of the People's Republic of China《中華人民共和國環境保護法》, the Law of the People's Republic of China on the Prevention and Control of Environment Pollution Caused by Solid Wastes《中華人民共和國固體廢棄物污染環境防治法》, the Water Pollution Prevention and Control Law of the People's Republic of China《中華人民共和國水污染防治法》and have formulated systems such as the Management Procedures for Three Wastes Discharge and Noise Control《三廢排放及噪聲控制管理規程》and the Hazardous Waste Management System《危險廢棄物管理制度》to take preventive measures against emissions such as exhaust gas, wastewater, and solid waste to ensure stable and compliant discharge of pollutants. The emission-generating departments shall accept the guidance and supervision of the regulatory authorities, and effectively implement the emission management regulations. In the event of any environment-polluting emergencies in the laboratory, we require R&D personnel to confirm their severity and report to the EHS commissioner as soon as possible. The EHS commissioner will issue an early warning according to the situation and require the responsible persons to prepare emergency supplies and take timely measures to ensure the safety of personnel and minimise the pollution to the surrounding environment.

Adhering to the concept of green operations, the Group has set up annual environmental goals and monitors their achievement to reduce the impact of production and operations on the environment. Additionally, various measures have been taken to promote the prevention and control of all kinds of emissions. In 2024, all of our environmental goals were realised.

Suzhou Manufacturing Plant's Environmental Goals in 2024

- Discharge of wastewater and waste gas up to the standards, with a rate of **100%**
- Disposal of solid wastes in compliance with the standards, with a rate of **100%**
- **0** environmental pollution incident
- **0** governmental punishment

In terms of exhaust gas and wastewater treatment, we use a two-stage activated carbon filtering and adsorption device to treat the laboratory waste gas, with a treatment efficiency of more than 80%. Based on the project environmental impact assessment report and the relevant national self-monitoring standards, we have prepared the environmental protection self-testing program, and entrusted third parties to conduct regular monitoring of waste gas, wastewater, rainwater and noise. We apply Fenton oxidation and coagulant sedimentation technologies to oxidise and degrade organic pollutants in the wastewater, thereby ensuring compliant discharge. In 2024, we upgraded our wastewater treatment facilities by adding online monitoring devices for pH and CODcr, alarm systems, and emergency treatment devices. This ensured that wastewater exceeding standards was temporarily stored or treated, preventing it from directly entering the wastewater treatment system and causing excessive discharge.

For hazardous wastes, we have established a hazardous waste pollution prevention and control leadership group headed by the CEO and leaders of various departments to make decisions, supervise, and coordinate the company's environmental protection work. Hazardous waste will be packaged with materials that are easy to recycle, dispose of or degrade in the environment. At the same time, we have signed disposal contracts on hazardous waste with third-party professional companies to ensure proper disposal of hazardous waste generated during experiments.

In terms of green office, we encourage paperless office by minimising copy, printing and advocate double-sided printing and wastepaper recycling to avoid unnecessary use of paper and reduce the amount of non-hazardous waste. We also actively answer the call for garbage classification by promoting it among employees and implementing it in offices with garbage classified into four categories: dry waste, wet trash, hazardous refuse, and recyclable waste.

In 2024, the Group's emission-related KPIs are shown as follows:

Environmental KPIs [1,2]	Unit	2024	2023
Total hazardous waste emission[3]	tonne	36.21	21.77
Hazardous waste emission intensity	kg per million RMB revenue	86.77	88.37
Total wastewater	tonne	8,779.34	5,138.79

Notes:

1. Environmental impacts from offices and laboratories are relatively limited, thus KPI A1.1 (The types of emissions and respective emissions data) and A1.4 (Total non-hazardous waste produced and intensity) have no material impact on the Group's operation, and are not disclosed in the ESG Report. In the future, we will continuously monitor the environmental impacts of our operation and disclose relevant environmental data in future reports when appropriate.

2. In 2024, the Group officially commenced in-house pharmaceutical production, leading to a significant increase in total hazardous waste emission and total wastewater.

3. Hazardous wastes generated by the Group mainly comes from experimental waste, organic solvent waste, unqualified products, waste acid and other hazardous waste generated during the experimental and production processes.

The environment and natural resources

Apart from the matters disclosed above, we do not cause other significant environmental impacts or make heavy use of other environmental and natural resources during operation. Therefore, Aspect A3 (The environment and natural resources) and KPI A3.1 (Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them) are not applicable to the Group, and are not disclosed in the ESG Report.

Climate change

Aware of the potential impact of climate change on human health, global trade and green development, Ocumension takes the initiative to identify the risk of climate change and assess the impacts of climate change to continuously enhance its ability to cope with climate change. After assessment, we believe that extreme weather events such as typhoons, strong winds, thunderstorms, rainstorms, cold waves, frost, and snowstorms may have impacts on the Group's normal operation.

Ocumension has formulated the Guidelines for Work Arrangements in Severe Weather《惡劣天氣工作安排指引》 to ensure the attendance and work safety of employees in extreme weather. In order to operate and carry out production as usual in the event of a major natural disaster, we formulated the Extreme weather response strategies《極端天氣應對策略》to provide safety instructions for employees during extreme weather events and set up an emergency team. We have contingency plans for different extreme weather events. By optimizing the corresponding emergency response strategies and processes, we minimize the impact of disasters on the Group and our employees' health.



In 2024, the Group's greenhouse gas emissions are shown as follows:

Environmental KPIs	Unit	2024	2023
Total GHG emissions (Scopes 1 and 2)[1]	tCO_2e	7,094.72	5,252.80
Direct GHG emissions (Scope 1)	tCO_2e	18.94	744.90
Including: Petrol	tCO_2e	13.33	13.33
Including: Natural gas	tCO_2e	5.62	731.57
Indirect GHG emissions from energy consumption (Scope 2)	tCO_2e	7,075.78	4,507.90
Including: Purchased electricity	tCO_2e	3,516.23	3,189.85
Including: Purchased steam	tCO_2e	3,559.55	1,318.05
GHG emission intensity	tCO_2e per million RMB revenue	17.00	21.32

Note:

1. Based on the nature of the Group's business operation, our GHG emissions mainly consist of direct GHG emissions (Scope 1) from gasoline consumption of vehicles, consuming purchased natural gas during production and operations and energy indirect GHG emissions (Scope 2) from purchased electricity. purchased electricity during production and operations were calculated in accordance with the 2022 Average Emission Factor of China's Power Grid of 0.5366 tCO_2/MWh issued by the Ministry of Ecology and Environment, while other greenhouse gas emissions were calculated according to the Guidelines for Accounting and Reporting Greenhouse Gas Emissions of Other Industrial Enterprises《工業其他行業企業溫室氣體排放核算方法與報告指南》.

Community Engagement in Creating a Vision of Light

Contribution to the SDGs

Guided by the principle of "Virtus et Lumen" (Courage and Light), Ocumension strives to create greater value for patients, communities, and the medical industry. In compliance with Chinese laws and regulations, we regulate our public welfare activities through the Compliance Manual《合规手册》. In addition, we fulfil our corporate social responsibility every year through co-host free clinics, patient education, co-host academic conferences, charity donations, and medical professional sponsorship.

Patient education

The Group has established the "Uveitis Matters" WeChat official account, dedicated to popularizing knowledge about uveitis and related ophthalmic diseases. This provides patients, their families, and medical professionals with comprehensive and accurate disease information, including definitions, causes, symptoms, diagnosis, and treatment methods of the diseases. On the WeChat official account, we share the latest treatment advancements and research findings, such as the application of biologics in refractory uveitis. Additionally, we provide psychological support to patients through sharing patient stories and case studies. Patients can learn about the common sense of eye protection, as well as the classification of and treatment plans for uveitis and other ophthalmic diseases through courses in Easy Vision. Meanwhile, we work together with the Department of Uveitis of Eye Hospital of Wenzhou Medical University and have built the Putao Tang, a patient-caring platform, to give lectures on ophthalmic knowledge every month to help the patients resolve their concerns. In 2024, a total of 13 online patient communication meetings were held through the "Uveitis Matters", and the number of followers of the official account has exceeded 5,000. In addition, we joined hands with JD Health's pharmacy service to launch eye care education activities, promoting knowledge about eye health.

Eye care education activities



Patient support

Ocumension is dedicated to identifying, developing, and commercializing first- or best-in-class ophthalmic therapies. In 2023, the Group's core products OT-502 were subject to Real World Research in the Hainan Boao Lecheng International Medical Tourism Pilot Zone, completing the data collection of 263 patients for the real-world research. In April 2024, our Phase III clinical trial of OT-502 achieved its primary endpoint. Though the real-world research, we are able to provide support for the evaluation of the efficacy and safety for patients with ophthalmic diseases. We are also continuing to advance more collaborative projects in the hope that more patients can benefit earlier. In the process of collecting real-world data in 2024, we recruited many patients and provided them with free treatment drugs and support, with a total investment of RMB 2.98 million.

Industry support

Ocumension actively participates in and promotes industry exchanges and cooperation, committed to promoting innovation and development of ophthalmic medical technology through various efforts. In 2024, we actively participated in, hosted, or co-hosted industry exchange events, including the 28th Congress of Chinese Ophthalmological Society of the Chinese Medical Association, the 7th Pharmaceutical Innovation Ecological Conference, and the Symposium for Education Leadership Training in Ophthalmology hosted by the Chinese Medical Women's Association.

The 28th Congress of Chinese Ophthalmological Society of the Chinese Medical Association (2024CCOS)

The 28th Congress of Chinese Ophthalmological Society of the Chinese Medical Association

In September 2024, Ocumension, a leading ophthalmic enterprise, worked with the Chinese Ophthalmological Society of the Chinese Medical Association as a "highest-level" partner to host ophthalmology academic congress this year. The congress attracted over 15,000 experts and scholars to participate. With the future as the goal and development as the main focus, this congress brought together academic wisdom in ophthalmic health from both domestic and overseas communities. Over 500 distinguished speakers were invited, delivering more than 500 specialized presentations and hosting nearly 200 continuing education lectures. Additionally, a total of 14 thousand paper submissions were received. This congress not only provided a platform for ophthalmologists to exchange and learn, but also promoted the innovation and development in ophthalmic medical technologies, contributing Chinese wisdom and expertise to the global ophthalmology community.

The 3rd Boao International Conference on Real World Studies of Medical Products

In 2024, Ocumension sponsored the 3rd Boao International Conference on Real World Studies of Medical Products. With the theme of "Real-World Studies Empowering Clinical Evaluation on Innovative Medical Products", this conference attracted over 800 experts, scholars, and guests from international organizations, domestic and overseas review agencies in medical products, well-known medical institutions, top research institutions and universities, as well as multinational enterprises in medical products. The conference aimed to share the latest scientific concepts of medical product regulation and demonstrate advanced scientific research achievements, thereby jointly promoting the development of global health initiatives.

The 7th Pharmaceutical Innovation Ecological Conference

In April 2024, Ocumension delivered a keynote speech at the 7th Pharmaceutical Innovation Ecological Conference. As an influential high-end and forward-looking industry conference in China's pharmaceutical innovation sector, this year's Pharmaceutical Innovation Ecological Conference attracted over 3,000 professionals from various segments of the pharmaceutical innovation sector, includingincluding "industry", "academia", "research", "medicine", "capital", and "commerce".Experts and scholars conducted nearly ten high-quality forums on hot topics such as industry-medicine integration and commercialization and internationalization of innovative drugs, exchanging and discussing industry experience together.

Adolescents by the Eye Protection Institution

As Ocumension's first approved project of the national key R&D programme of the Ministry of Science and Technology of the PRC and one of the major special projects under the 14th Five-year Plan, the Research on Precise Prevention Technology and Demonstration Application of Myopia in Children focuses on the pathogenesis, treatment plan, and three-level prevention of myopia in children, and has established a comprehensive prevention and control system for myopia in children that is in line with the national conditions of China. It decreases the occurrence and development of myopia in Chinese children and reduces people's blindness and visual impairment.

In 2024, we continued this project and obtained a regional certificate of registration for low-concentration atropine sulfate eye drops. Also, we participated in the publication of the Expert Consensus on Preparation of Low-Concentration Atropine Sulfate for Myopia Progression Control (2023)《低濃度硫酸阿托品防控近視進展眼用製劑製備的專家共識(2023)》, and in the development of industry standards for low-concentration atropine sulfate eye drops. Meanwhile, the multicentre, randomized, controlled clinical trial on the prevention and control of myopia with low-concentration atropine sulfate eye drops has entered the final phase. This project is expected to provide practical assistance and support for the targeted prevention and control of childhood myopia in China.

Special Project of the Ministry of Science and Technology by Shanghai Jiao Tong University

In 2024, as a major special project of the national key R&D programme of Research on the Prevention and Treatment of Common and Frequently-occurring Diseases, the project: the Construction of Multidimensional Big Data-driven Precise Prevention of and Intervention Strategy for Common Blindness-related Ophthalmic Diseases in China continues, which was participated by the Group and applied under the initiative of Shanghai Jiao Tong University. The project will play a positive role in promoting the development and marketing of products for cataract, glaucoma, and myopia in China, and will make a social contribution to reducing blindness and visual impairment in the population.

Medidata NEXT China 2024

The 13th Medidata NEXT China 2024 was held in Shanghai on September 6, 2024. The conference brought together over 600 experts and scholars from the global life sciences field to delve into the pivotal roles of artificial intelligence (AI) and decentralized clinical trials (DCT) in the future development of clinical trials.

Medidata NEXT China 2024

The Symposium for Education Leadership Training in Ophthalmology hosted by the Chinese Medical Women's Association

The Symposium for Education Leadership Training in Ophthalmology hosted by the Chinese Medical Women's Association was held in Shantou in November 2024. Based on the practical teaching needs of ophthalmologists and educators, this symposium invited numerous domestic and overseas experts and professors to deliver a diverse range of practical and innovative courses throughout the two-day agenda. Participants were provided with valuable guidance on teaching strategies, teaching tools, and evaluation systems, comprehensively enhancing the teaching capabilities of ophthalmology educators.

Standard Establishment

Ocumension actively participates in the compilation of industry standards, contributing to the collective progress of the industry. During the Reporting Period, the T/SMA 0048-2024 Specification for the Preparation of Low-Concentration Atropine Sulfate Eye Drops 《TSMA 0048-2024 低濃度硫酸阿托品眼用製劑製備規範》, which we participated in compiling, was officially released. This demonstrated Ocumension's professional expertise in the field of ophthalmology and its active commitment to the establishment of industry standards.

Appendix: Index for ESG Reporting Guide

Aspect	Description	Title of sections
A1	**Emissions**	
General Disclosure	(a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to air and greenhouse gas emissions, discharges into water and land, and generation of hazardous and non-hazardous waste.	
A1.1	The types of emissions and respective emissions data.	Low-Carbon and Environmentally Friendly Practices for Green Development -Emissions management
A1.2	Direct (Scope 1) and energy direct (Scope 2) greenhouse gas emissions (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	
A1.3	Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	
A1.4	Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	
A1.5	Description of emission target(s) set and steps taken to achieve them.	
A1.6	Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.	
A2	**Use of Resources**	
General Disclosure	Policies on the efficient use of resources, including energy, water and other raw materials.	Low-Carbon and Environmentally Friendly Practices for Green Development -Resources management
A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).	
A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility).	
A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them.	
A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.	
A2.5	The total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.	
A3	**The Environment and Natural Resources**	Low-Carbon and Environmentally Friendly Practices for Green Development - The environment and natural resources
General Disclosure	Policies on minimising the issuer's significant impacts on the environment and natural resources.	
A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	
A4	**Climate Change**	Low-Carbon and Environmentally Friendly Practices for Green Development -Climate change
General Disclosure	Policies on identification and mitigation of significant climate-related issues which have impacted, and those which may impact, the issuer	
A4.1	Description of the significant climate-related issues which have impacted, and those which may impact, the issuer, and the actions taken to manage them.	

B1	**Employment**	
General Disclosure	(a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare.	Diversity and Inclusion for Employee Development - Compliance employment, Compensation and benefits
B1.1	Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region.	
B1.2	Employee turnover rate by gender, age group and geographical region.	

B2	**Health and Safety**	
General Disclosure	(a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards	Diversity and Inclusion for Employee Development - Health and safety
B2.1	Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.	
B2.2	Lost days due to work injury.	
B2.3	Description of occupational health and safety measures adopted and how they are implemented and monitored.	

B3	**Development and Training**	
General Disclosure	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities.	Diversity and Inclusion for Employee Development - Development and training
B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management).	
B3.2	The average training hours completed per employee by gender and employee category.	

B4	**Labour Standards**	
Genteral Disclosure	(a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labour.	Diversity and Inclusion for Employee Development - Compliance employment
B4.1	Description of measures to review employment practices to avoid child and forced labour.	
B4.2	Description of steps taken to eliminate such practices when discovered.	

B5	**Supply Chain Management**	
Genteral Disclosure	Policies on managing environmental and social risks of the supply chain.	
B5.1	Number of suppliers by geographical regions.	R&D Innovation for Health Accessibility - Responsible supply chain
B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.	
B5.3	Description of practices used to identify environmental and social risks along the supply chain, and how they are implemented and monitored.	
B5.4	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	
B6	**Product Responsibility**	
Genteral Disclosure	(a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.	R&D Innovation for Health Accessibility - Full life-cycle management; Responsible Operation to Consolidate Development Foundation - Information security and privacy protection
B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons.	
B6.2	Number of products and service-related complaints received and how they are dealt with.	
B6.3	Description of practices relating to observing and protecting intellectual property rights.	
B6.4	Description of quality assurance process and recall procedures.	
B6.5	Description of consumer data protection and privacy policies, and how they are implemented and monitored.	
B7	**Anti-corruption**	
Genteral Disclosure	(a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.	Responsible Operation to Consolidate Development Foundation - Business ethics
B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.	
B7.2	Description of preventive measures and whistle-blowing procedures, how they are implemented and monitored.	
B7.3	Description of anti-corruption training provided to directors and staff.	
B8	**Community Investment**	
General Disclosure	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests.	Community Engagement in Creating a Vision of Light
B8.1	Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture,sport).	
B8.2	Resources contributed (e.g. money or time) to the focus area.	

Ocumension Therapeutics
歐康維視生物